Cisplatin Induced Nephrotoxicity
Cisplatin is a potent chemotherapy agent which is used to treat a broad spectrum of solid cancers. However, its clinical use is limited due to its nephrotoxicity with a decline in the glomerular filtration rate that occur in 15-30% of patients. Multiple mechanisms contribute to renal dysfunction fol...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Birjand University of Medical Sciences and Health Services
2014-02-01
|
| Series: | مجله دانشگاه علوم پزشکی بیرجند |
| Subjects: | |
| Online Access: | http://journal.bums.ac.ir/browse.php?a_code=A-10-432-3&slc_lang=en&sid=1 |
| _version_ | 1828824222255808512 |
|---|---|
| author | Seyed Seifollah Beladi Mousavi Abbas Ali Zeraati |
| author_facet | Seyed Seifollah Beladi Mousavi Abbas Ali Zeraati |
| author_sort | Seyed Seifollah Beladi Mousavi |
| collection | DOAJ |
| description | Cisplatin is a potent chemotherapy agent which is used to treat a broad spectrum of solid cancers. However, its clinical use is limited due to its nephrotoxicity with a decline in the glomerular filtration rate that occur in 15-30% of patients. Multiple mechanisms contribute to renal dysfunction following exposure to cisplatin include tubular epithelial cell toxicity, vasoconstriction in the renal microvasculature, and increase the expression of proinflammatory cytokines.
The most important manifestations of cisplatin nephrotoxicity are non oliguric acute renal failure (ARF) which can be progressive, hypomagnesemia, fanconi-like syndrome, and anemia. An increasing risk of ARF is associated with higher doses of cisplatin, previous cisplatin chemotherapy, underlying kidney dysfunction, and the concomitant use of other nephrotoxic agents.
The standard approach to prevent cisplatin-induced nephrotoxicity is the administration of lower doses of cisplatin in combination with the administration of full intravenous isotonic saline before and after cisplatin administration. Although a number of pharmacologic agents including sodium thiosulfate, N-acetylcysteine, theophylline and glycine have been evaluated for prevention of nephrotoxicity, none have proved to have an established role, thus, additional clinical studies will be required to confirm their probable effects. |
| first_indexed | 2024-12-12T13:52:15Z |
| format | Article |
| id | doaj.art-575aa800358f47daa58965f7924d9be7 |
| institution | Directory Open Access Journal |
| issn | 1607-2197 2423-6152 |
| language | fas |
| last_indexed | 2024-12-12T13:52:15Z |
| publishDate | 2014-02-01 |
| publisher | Birjand University of Medical Sciences and Health Services |
| record_format | Article |
| series | مجله دانشگاه علوم پزشکی بیرجند |
| spelling | doaj.art-575aa800358f47daa58965f7924d9be72022-12-22T00:22:32ZfasBirjand University of Medical Sciences and Health Servicesمجله دانشگاه علوم پزشکی بیرجند1607-21972423-61522014-02-01204327337Cisplatin Induced NephrotoxicitySeyed Seifollah Beladi Mousavi0Abbas Ali Zeraati1 Chronic Renal Failure Research Center, Ahwaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Kidney Transplantation Complications Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Cisplatin is a potent chemotherapy agent which is used to treat a broad spectrum of solid cancers. However, its clinical use is limited due to its nephrotoxicity with a decline in the glomerular filtration rate that occur in 15-30% of patients. Multiple mechanisms contribute to renal dysfunction following exposure to cisplatin include tubular epithelial cell toxicity, vasoconstriction in the renal microvasculature, and increase the expression of proinflammatory cytokines. The most important manifestations of cisplatin nephrotoxicity are non oliguric acute renal failure (ARF) which can be progressive, hypomagnesemia, fanconi-like syndrome, and anemia. An increasing risk of ARF is associated with higher doses of cisplatin, previous cisplatin chemotherapy, underlying kidney dysfunction, and the concomitant use of other nephrotoxic agents. The standard approach to prevent cisplatin-induced nephrotoxicity is the administration of lower doses of cisplatin in combination with the administration of full intravenous isotonic saline before and after cisplatin administration. Although a number of pharmacologic agents including sodium thiosulfate, N-acetylcysteine, theophylline and glycine have been evaluated for prevention of nephrotoxicity, none have proved to have an established role, thus, additional clinical studies will be required to confirm their probable effects.http://journal.bums.ac.ir/browse.php?a_code=A-10-432-3&slc_lang=en&sid=1Cisplatin Cisplatin nephrotoxicity chemotherapy |
| spellingShingle | Seyed Seifollah Beladi Mousavi Abbas Ali Zeraati Cisplatin Induced Nephrotoxicity مجله دانشگاه علوم پزشکی بیرجند Cisplatin Cisplatin nephrotoxicity chemotherapy |
| title | Cisplatin Induced Nephrotoxicity |
| title_full | Cisplatin Induced Nephrotoxicity |
| title_fullStr | Cisplatin Induced Nephrotoxicity |
| title_full_unstemmed | Cisplatin Induced Nephrotoxicity |
| title_short | Cisplatin Induced Nephrotoxicity |
| title_sort | cisplatin induced nephrotoxicity |
| topic | Cisplatin Cisplatin nephrotoxicity chemotherapy |
| url | http://journal.bums.ac.ir/browse.php?a_code=A-10-432-3&slc_lang=en&sid=1 |
| work_keys_str_mv | AT seyedseifollahbeladimousavi cisplatininducednephrotoxicity AT abbasalizeraati cisplatininducednephrotoxicity |